Drugs / Daklatasuvir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03444272 | Jan 2018 → Dec 2022 | hepatitis C virus infection | Tanta University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03402165 | Jan 2017 → Dec 2022 | hepatitis C virus infection | Tanta University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daklatasuvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03444272 ↗ |